查看文章

Objective: In patients with amyotrophic lateral sclerosis, long term treatment with riluzole has been reported to improve survival or tracheostomy-free survival in comparison with placebo. We conducted a pharmacoeconomic analysis for estimating the cost per life-year gained using this drug.

Design: This study was an incremental cost-effectiveness lifetime analysis.

Setting: The clinical material was derived from 2 placebo-controlled randomized controlled trials comparing riluzole versus usual care without riluzole, which were identified through a literature search based on the IOWA and the Medline systems.

Patients and interventions: The study included 633 patients with amyotrophic lateral sclerosis. Patient-level information was retrieved from313 patients treated with riluzole and 320 patients assigned to placebo.

Survival after …